Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Condition: COVID-19 Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector); Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo Sponsors: CanSino Biologics Inc.; Beijing Institute of Biotechnology; Jiangsu Province Centers for Disease Control and Prevention Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenoviruses | Biotechnology | Centers for Disease Control and Prevention (CDC) | Clinical Trials | Coronavirus | COVID-19 | Research | Vaccines